slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 67,951-67,980
Pages 3,679
Rows per page 30
Component
67,951-67,980 of 110,355
10
The slide uses a vertical process flow to demonstrate clinical progression and de-risking.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Beat · Traction1 hit
11
The slide highlights the efficacy of RL-007 in cognitive endpoints during a Phase 2 study.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
12
The slide uses a standard clinical trial flow diagram to illustrate the study protocol.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
13
The slide uses a feature-comparison matrix to highlight the competitive advantage of RL-007.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
15
The slide uses a split-layout: left side defines the disease and market size, right side outlines the clinical 'urgent need' for innovation.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The slide uses a line chart to demonstrate the efficacy of different dosages of COMP360 over 12 weeks.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
17
The slide uses a timeline-based process diagram to illustrate clinical trial protocols.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
18
The slide uses a split layout: a left-hand sidebar for product summary and a right-hand side for clinical data visualization.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
21
The slide uses a combination of a disease overview, market sizing metrics, and a 'massive unaddressed need' framework to justify the problem.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
22
Includes a comparison chart of Etifoxine vs Lorazepam and a summary of Phase 1 trial design.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
23
Includes detailed TEAE (Treatment-emergent Adverse Event) breakdown by dose cohort.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
24
The slide uses topographical brain maps to visualize EEG data changes across three cohorts (Placebo, Low Dose, High Dose).ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
25
The chart displays pharmacodynamic data with error bars and significance markers (asterisks).ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
26
The slide uses a checkmark matrix to highlight the competitive advantages of the proposed drug.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
28
Uses a timeline-style visual to list key statistics about the OUD crisis.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
29
Includes a line chart showing HCQN subscale scores over time and a two-stage clinical trial design diagram.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Loop · Why Now1 hit
30
The slide uses a checkmark-based comparison matrix to highlight the unique value proposition of DMX-1002.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Loop · Why Now1 hit
32
The slide uses a structured card-based layout to present four distinct business units.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
03
The slide uses a three-column layout to define the business model and provides quantitative evidence for each pillar at the bottom.Babylon | Investor Conference Presentation Deck | 19 slides · Babylon
Conference presentation Investor relations Beat · Setup1 hit
07
The funnel represents a care delivery hierarchy. The right side shows a visual correlation between care level, cost ($), and population size (Millions).Babylon | Investor Conference Presentation Deck | 19 slides · Babylon
Conference presentation Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
11
VBC = Value-Based Care. Data points include margin percentages and member sign-up percentages.Babylon | Investor Conference Presentation Deck | 19 slides · Babylon
Conference presentation Investor relations Beat · EvidenceLoop · Cost Of Inaction1 hit
12
The slide uses a horizontal process flow to map business model components to revenue outcomes.Babylon | Investor Conference Presentation Deck | 19 slides · Babylon
Conference presentation Investor relations Beat · Development1 hit
13
The slide highlights CAGR for both metrics.Babylon | Investor Conference Presentation Deck | 19 slides · Babylon
Conference presentation Investor relations Beat · DevelopmentLoop · Pareto Focus1 hit
14
The chart highlights a 4.8x YoY VBC revenue growth and a shift in revenue mix towards Medicare and commercial populations.Babylon | Investor Conference Presentation Deck | 19 slides · Babylon
Conference presentation Investor relations Beat · DevelopmentLoop · Pareto Focus1 hit
16
The slide uses a stylized path diagram to connect four key financial updates.Babylon | Investor Conference Presentation Deck | 19 slides · Babylon
Conference presentation Investor relations Beat · Development1 hit
16
The chart uses a segmented bar approach to compare established industry players against BenevolentAI's projected output.BenevolentAI | Investor Conference Presentation Deck | 29 slides · BenevolentAI
Conference presentation Investor relations Beat · Action1 hit
19
The slide uses a two-column layout to contrast the disease burden (left) with the proposed therapeutic solution (right).BenevolentAI | Investor Conference Presentation Deck | 29 slides · BenevolentAI
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
20
Includes specific caveats regarding study power and dosing duration.BenevolentAI | Investor Conference Presentation Deck | 29 slides · BenevolentAI
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
21
The slide uses a split-column layout to contrast the disease burden/market need (left) with the proposed solution/mechanism (right).BenevolentAI | Investor Conference Presentation Deck | 29 slides · BenevolentAI
Conference presentation Investor relations Beat · Action1 hit
03
The slide uses a stacked area chart to represent historical innovation waves and a vertical list of metrics to quantify the current gene/cell therapy market.Berkeley Lights | Investor Conference Presentation Deck | 26 slides · Berkeley Lights
Conference presentation Investor relations Beat · Current Reality (Pain)Loop · Aha Moment1 hit